



Airway Therapeutics, based in Atlanta, GA, is a clinical-stage biopharmaceutical company advancing a new class of biologic therapies to drive a step change in the prevention and treatment of multiple respiratory inflammatory diseases, across all age groups.

Lead Asset, Zelpultide Alfa: Redefining Standard of Care for Bronchopulmonary Dysplasia (BPD)

Zelpultide alfa is a first-in-class recombinant protein that replicates the structural and functional biology of native SP-D, a protein that modulates the immune response, regulates inflammation and aids in pathogen clearance.

- **Immunomodulation:** Regulates TLR4 signaling and cytokine release to reduce inflammation and prevent tissue damage.
- **Immune Defense:** Facilitates pathogen recognition through pathogen associated molecular patterns (PAMPs), promoting opsonization and rapid clearance by immune cells.
- **Surfactant homeostasis:** Recycles alveolar lipids to maintain lung compliance.

BPD: Leading Cause of Lung Disease in Premature Neonates Resulting in Lifelong Health Risks

BPD is a serious lung condition with no approved therapies affecting ~50% of preterm infants (<28 weeks gestational age)

- Phase 1b data demonstrated **no dose-limiting toxicities** and **meaningful improvements across BPD severity, survival, ventilation and hospitalization duration**
- **First patient dosed in Pivotal Phase 2b/3 trial in Q4 2025 with potential BLA submission by Q2 2028**
- Trial approved to proceed in US, EU (7 countries), Israel and Argentina.
- Orphan Drug Designation for BPD granted by FDA and EMA

Large global commercial opportunity in BPD alone with ~425K neonates at risk annually and high economic burden (~\$700K hospitalization cost in year one)

- Premature infant lungs lack SP-D, and 50-80% of those born before 28 weeks need respiratory support to survive
- Current standard of care uses commercial surfactant, which lacks SP-D, and cannot protect against lung damage

Pipeline

Indication	Discovery	Pre-IND	IND Approval	Phase 1	Phase 2	Phase 3
BPD						
Pneumonia / Flu / ARDS						
COPD						
Pulmonary Fibrosis						

Potential Additional Indications:

- Asthma
- RSV

**BPD= Bronchopulmonary Dysplasia; ARDS = Acute Respiratory Distress Syndrome; COPD = Chronic Obstructive Pulmonary Disease; RSV = Respiratory Syncytial Virus*

Leadership Team



Marc Salzberg, MD
CEO, Chairman

- 30+ years in academic medicine & pharma industry
- Former Head of Clinical Cancer Research, University of Basel
- Founder & President, Pharma Brains CRO → acquired by Medpace
- Former VP of Medical Affairs, Medpace



Alan S. Wolk, MBA
CFO, COO

- 30+ years in business management & financial operations
- Former President, \$2B+ Interiors Division at DuPont & Invista
- Former CFO, DuPont Nylon & DuPont's Pharma/Diagnostics
- Led major M&A, JVs & divestitures worldwide
- Drove DuPont–Merck JV → launch of Cozaar®